Patrick Wood
Stock Analyst at Morgan Stanley
(3.84)
# 788
Out of 4,555 analysts
59
Total ratings
50%
Success rate
11.13%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Initiates: Equal-Weight | $45 | $42.24 | +6.53% | 1 | Aug 22, 2024 | |
| DXCM DexCom | Maintains: Equal-Weight | $120 → $75 | $69.71 | +7.59% | 6 | Jul 26, 2024 | |
| RBOT Vicarious Surgical | Maintains: Equal-Weight | $18 → $10 | $5.92 | +68.92% | 2 | Jul 15, 2024 | |
| GKOS Glaukos | Maintains: Equal-Weight | $100 → $120 | $129.40 | -7.26% | 2 | Jul 15, 2024 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $104 → $145 | $139.31 | +4.08% | 1 | Jul 15, 2024 | |
| SOLV Solventum | Maintains: Equal-Weight | $70 → $55 | $67.03 | -17.95% | 2 | Jul 15, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $79 → $92 | $82.65 | +11.31% | 3 | Jul 15, 2024 | |
| ALC Alcon | Upgrades: Equal-Weight | $65 → $85 | $96.49 | -11.91% | 3 | Jul 15, 2024 | |
| STAA STAAR Surgical Company | Downgrades: Underweight | $50 → $37 | $30.05 | +23.13% | 2 | Jul 15, 2024 | |
| BAX Baxter International | Downgrades: Underweight | $39 → $30 | $39.23 | -23.53% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $15.75 | +14.29% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $103 | $65.71 | +56.75% | 6 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $86 | $85.12 | +1.03% | 5 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $225 → $215 | $245.50 | -12.42% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $103 → $89 | $108.03 | -17.85% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $310 → $280 | $237.22 | +18.03% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $185 → $234 | $219.13 | +6.79% | 4 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $245.04 | - | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $53.55 | -32.77% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $150.24 | - | 1 | Dec 11, 2017 |
Tandem Diabetes Care
Aug 22, 2024
Initiates: Equal-Weight
Price Target: $45
Current: $42.24
Upside: +6.53%
DexCom
Jul 26, 2024
Maintains: Equal-Weight
Price Target: $120 → $75
Current: $69.71
Upside: +7.59%
Vicarious Surgical
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $5.92
Upside: +68.92%
Glaukos
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $100 → $120
Current: $129.40
Upside: -7.26%
TransMedics Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $139.31
Upside: +4.08%
Solventum
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $70 → $55
Current: $67.03
Upside: -17.95%
Boston Scientific
Jul 15, 2024
Maintains: Overweight
Price Target: $79 → $92
Current: $82.65
Upside: +11.31%
Alcon
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $96.49
Upside: -11.91%
STAAR Surgical Company
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $30.05
Upside: +23.13%
Baxter International
Jul 15, 2024
Downgrades: Underweight
Price Target: $39 → $30
Current: $39.23
Upside: -23.53%
May 6, 2024
Upgrades: Overweight
Price Target: $16 → $18
Current: $15.75
Upside: +14.29%
Mar 21, 2024
Maintains: Overweight
Price Target: $95 → $103
Current: $65.71
Upside: +56.75%
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $74 → $86
Current: $85.12
Upside: +1.03%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $245.50
Upside: -12.42%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $103 → $89
Current: $108.03
Upside: -17.85%
Dec 4, 2023
Maintains: Overweight
Price Target: $310 → $280
Current: $237.22
Upside: +18.03%
Dec 4, 2023
Upgrades: Overweight
Price Target: $185 → $234
Current: $219.13
Upside: +6.79%
Dec 4, 2023
Upgrades: Overweight
Price Target: n/a
Current: $245.04
Upside: -
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $53.55
Upside: -32.77%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $150.24
Upside: -